Medical Big Data

Revolutionary Pharmacy Analytics Platform Uses Real Patient Data

Agilum Healthcare

Agilum Healthcare Intelligence partners with LIU Pharmacy to advance evidence-based care

Agilum Healthcare Intelligence and Long Island University Pharmacy have joined forces to offer an innovative post-doctoral fellowship program centered on using Agilum’s industry-leading, proprietary analytics platform, Comparative Rapid Cycle Analytics™ (CRCA) P&T, to analyze real-world data and real-world evidence to improve patient outcomes and reduce the total cost of care.

“Agilum’s longitudinal, pharmacy-centric patient database is disrupting the way clinicians practice medicine by arming them with near real-time, evidence-based care treatment recommendations – literally within minutes,” said Travis Leonardi, RPh, CEO of Agilum and Sentry Data Systems. “I’ve always maintained that drugs are the cornerstone of all healthcare outcomes and that higher quality, more effective drug regimens will always yield a manageable total cost of care.”

Agilum’s partnership with LIU Pharmacy will further facilitate the critical work of training the next generation of pharmacy leaders in how to use technology to revolutionize healthcare.

As part of the program, the fellows will spend two years working alongside faculty and staff at LIU Pharmacy’s drug information center and the experts at Agilum to identify areas of unmet need in assessing the efficacy, costs and outcomes of pharmaceutical drugs. The fellows will have full access to CRCA P&T, a longitudinal database that contains records from tens of millions of de-identified patients across the entire country, to generate real-world evidence identifying the most efficacious patient care regimens.

CRCA P&T can compare treatments, drugs, processes and costs. The fellows’ findings will be used by clinicians and health systems to inform clinical decision-making on treatment protocols, assess patients’ treatment compliance and monitor the safety of interventions.

Related posts

AdventHealth & Sema4 Launch Data-driven Precision Medicine Program

Business Wire

Precision Oncology Leader to Participate at Investment Conference

Business Wire

Sema4 and CM Life Sciences File the Schedule-14A Proxy Statement

Business Wire